Lv31
320 积分 2023-10-17 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
1小时前
待确认
EBV-Upregulated B7-H3 Inhibits NK cell–Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression
13天前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
2个月前
已完结
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)
2个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
2个月前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
2个月前
已完结
A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications
3个月前
已完结
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
4个月前
已完结
Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST
4个月前
已完结
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
4个月前
已完结
皖公网安备34019202002308
